Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

Austrian research expenditures expected to rise 3.8% to EUR 11.33 billion

researcher © Richard Tanzer

“We are consciously focusing on this. Innovations are decisive for the competitiveness of the business location and also ensure valuable jobs. The further increase of the research quota shows than our measures are having a positive impact, and we rank among the best in European. We have to determinedly move ahead with this positive development. The next important step is the increase in the research premium for our companies to 14%”, says Reinhold Mitterlehner, Federal Minister of Science, Research and Economy.

Corporate sector accounts for largest share of R&D spending

The corporate sector accounts for the biggest share of R&D expenditures. EUR 5.46 billion or 48.2% of total research spending in Austria originate in the private sector, representing a 3% rise from the previous year.  

The public sector financed EUR 4.08 billion or 36% of total R&D expenditures in Austria, up 5.2% from the prior-year level. The statisticians said that the “main reason” for the strong increase was the research premium. The rise from 10% to 12% which took effect in 2016 means that about EUR 100 million more in funding was granted to domestic companies. On balance, the total research premium paid to companies in 2017 is expected to amount to EUR 627.7 million.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Business Breakfast Brno - Virtual Conference

    22.04.2020, Brno, Czech Republic

  • Corporate Day - Online Conference

    12.05.2020 / 13:00, Online Event

Austria Map

Find the perfect location for your company

Vienna’s unique location at the heart of Europe makes it an important centre and very popular with the global pharmaceutical and biotechnology industry. Vienna is where Eastern Europe meets Western Europe. Businesses located at this international hub benefit from well-established infrastructures and highly-qualified professionals. The significant growth in the Life Sciences sector in Vienna over the last few years is an indicator of the momentum in the industry.

ABF Pharmaceutical Services

ABF Pharmaceutical Services
More testimonials

news from the business location Austria

“Corona: Short-Time Work“

Short-time work is possible for companies regardless of their size and the respective sector in which they operate (with the exception of federal and provincial governments, municipalities, legal persons under public law and political parties).

Support Measures for Companies Affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts